2021
Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy
Lo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. American Journal Of Clinical Pathology 2021, 156: 214-228. PMID: 33555016, DOI: 10.1093/ajcp/aqaa217.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseCD8/FOXP3 ratioBiopsy specimensCPI patientsPD-1CD68 scoreFOXP3 ratioBowel diseasePD-L1Antibody-treated patientsCheckpoint inhibitor colitisPD-L1 groupInitial biopsy specimensPD-L1 expressionImmune cell reactionsColonic biopsy specimensDrug-specific differencesIBD groupCheckpoint inhibitorsChronicity scoreActivity scoreImmune phenotypeTherapeutic responseColitisShared pathophysiology
2020
Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy
Patil PA, Zhang X. Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy. Archives Of Pathology & Laboratory Medicine 2020, 145: 571-582. PMID: 32338534, DOI: 10.5858/arpa.2020-0070-ra.Peer-Reviewed Original ResearchConceptsHepatobiliary injuryCheckpoint inhibitorsCPI therapyActive colitisPathologic manifestationsCytotoxic T-lymphocyte-associated protein 4 inhibitorsT-lymphocyte-associated protein 4 inhibitorsImmune checkpoint inhibitor therapyDeath ligand 1 (PD-L1) inhibitorsAdverse effectsChronic active colitisAdministration of steroidsCheckpoint inhibitor therapyDeath receptor-1Immune checkpoint inhibitorsBile duct injuryChronic active gastritisLigand 1 inhibitorsNodular regenerative hyperplasiaSecondary sclerosing cholangitisDifferential diagnostic considerationsProtein 4 inhibitorsSeverity of injuryIschemic colitisPanlobular hepatitis